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Summary Data concerning the determinants of sputum eosinophilia and bronchial
hyper-responsiveness (BHR) in large cohorts of individuals with normal lung function
are limited. Here, we assessed the occurrence of sputum eosinophilia and BHR and
identified the risk factors for these variables in two populations living in North
Karelia, Finland, and in Pitk.aranta, the Republic of Karelia, Russia. These areas are
geographically adjacent, but differ, however, fundamentally in major cultural,
socioeconomical and lifestyle aspects. The study population comprised 790 Finns
and 387 Russian, aged 25–54 years, who were randomly enrolled from the population
registers. A methacholine challenge test to measure BHR was successfully performed
in 581 (74%) Finns and 307 (79%) Russians with virtually normal lung function
(FEV1470% of predicted). Of these, induced sputum samples were obtained from 41%
of the Finns and from 67% of the Russians. The proportion of current smokers was 27%
among the former and 42% among the latter. Sputum eosinophilia was assessed using a
semi-quantitative method, and total concentrations of sputum eosinophilic cationic
protein (ECP) and myeloperoxidase (MPO) were measured using an immunoassay. Risk
factors for BHR and sputum eosinophilia were identified with a regression analysis. The
prevalence of sputum eosinophilia was 22% among the Finns and 19% among the
Russians, and the respective figures for BHR were 14% and 13%. The median ECP
concentration in sputum was significantly higher among the Russians as compared with
the Finns (Po0:001), whereas for MPO, the difference did not achieve significance.
Current smoking was significantly associated with both sputum eosinophilia and BHR in
Russia (OR 3.1, 95% CI 1.2–7.6 for sputum eosinophilia, 2.8, 1.3–6.1 for BHR) and with
BHR in Finland (2.1, 1.3–3.7). Atopy showed a tendency to be another risk factor for
BHR in Finland (1.6, 0.98–2.6). In conclusion, sputum eosinophilia and BHR occurred
commonly among the Finns and the Russians with normal lung function. Current
smoking was significantly associated with BHR in both countries and additionally with
sputum eosinophilia in Russia. Atopy was identified as a risk factor, albeit of borderline
significance, for BHR in Finland only, suggesting that there may be differences in the
aetiology and nature of BHR between the two countries.
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Introduction
In asthma, airway inflammation is found in virtually
all individuals with the disease.1,2 It is considered
the primary event leading to variable airway
obstruction and bronchial hyper-responsiveness
(BHR), and appear to be the critical factor in
determining disease severity.2,3 In this inflamma-
tion and pathogenesis of asthma, the eosinophil
constituents may play a major role by damaging,
desquamating of airway epithelial cells, altering
cilial function, and eliciting local oedema.4 Only
recently, the introduction of a novel noninvasive
method has made the direct measurement of
airway inflammation possible in larger population
studies. This analysis of induced sputum has been
shown to be a reproducible, valid and feasible
method for assessing eosinophilic inflammation in
the airways.3,5 Especially, the measurement of the
total concentration of eosinophilic cationic protein
(ECP), an eosinophil activation marker, and myelo-
peroxidase (MPO), a neutrophil marker, from lysed
cells, has proved to be a useful tool to examine the
nature and severity of inflammation in different
subject groups.5,6
BHR can exist independent of the bronchial
inflammatory response.1 However, there is also
evidence to suggest that BHR is secondary to
epithelial cell damage mediated through products
from inflammatory cells,4,7 and the degree of
eosinophil activation may be important in the
development of BHR.3,7 Changes in BHR have been
associated with changes in sputum inflammatory
indices, although the significance of correlations
between sputum parameters and BHR has shown a
considerable range of variation.3
Numerous studies have provided evidence that
the major factors involved in the substantial
increases in asthma and atopy prevalences during
the last few decades appear to be environmental
and associated with Western lifestyle.8,9 In our
previous study, we found significantly higher pre-
valences of atopy and allergic diseases (hay fever,
allergic eye symptoms, atopic eczema and asthma)
in Finland as compared with Russia, providing
support to the hypothesis that the rises in the
prevalences of allergic diseases are associated with
Western lifestyle. Moreover, only a part of the
differences in allergic diseases could be explained
by the difference in atopy.10 We took this unique
opportunity to further examine the prevalences
and risk factors of the two parameters associated
with airway inflammation, sputum eosinophilia and
BHR, which, as objective measurements, were
expected to allow reliable comparisons between
the two countries.
The aim of this study was, therefore, to assess
the early inflammatory changes by measuring the
occurrence of sputum eosinophilia and BHR in
individuals without clinically relevant lung function
impairment in Finland and Russia, and to identify
the major risk factors for these variables.
Materials and methods
Study population
This survey was carried out in 1998 in North Karelia
province in Finland, and in Pitk.aranta district in the
Republic of Karelia in Russia, two geographically
adjacent areas differing, however, fundamentally
in major cultural, socioeconomical and lifestyle
aspects. The recruitment procedure as well as the
study areas and populations have been described in
detail elsewhere.10 In brief, the population samples
of subjects aged 25–54 years, ethnically Cauca-
sians, were randomly drawn from the population
registers and stratified by 10-year age groups and
gender. Seven hundred and ninety subjects in
Finland and 387 subjects in Russia were recruited
preliminarily into the study. However, subjects in
whom a baseline forced expiratory volume in one
second FEV1¼o(i.e. equal or less than) 70% of
predicted had been measured were excluded from
the methacholine challenge test (32 Finns, 30
Russians). The other exclusion criteria were an
acute respiratory tract infection during the last 2
weeks, an acute myocardial or cerebral infarction
during the last 3 months, epilepsy, pregnancy or
breast feeding, regular use of asthma medication,
and regular use of a b-blocker. In addition, various
technical and practical reasons, such as incomplete
or otherwise unsuccessful blow, poor co-operation
or unwillingness to participate the challenge test,
reduced the population sample. Finally in 581
(73.5%) Finns and 307 (79.3%) Russians, the metha-
choline challenge test was successfully performed.
Of these subjects, an acceptable sputum sample
was obtained from 240 (41.3%) Finns and 205
(66.8%) Russians. Subject characteristics are pre-
sented in Table 1.
The questionnaire
The questionnaire used in the present study was a
modification of that used in the European Commu-
nity Respiratory Health Survey.11 It was carefully
tested for comprehensibility before the start of the
study, and was sent beforehand and self-adminis-
tered (Finland) or completed at the study site
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(Russia). The questionnaire included issues
concerning smoking habits, parental asthma, oc-
currence of respiratory symptoms and atopic
diseases. Subjects who reported that they
smoked regularly, were categorized as current
smokers, those who had been regular smokers but
quitted smoking for at least 1 year ago, were
considered as former smokers, and those who had
never smoked regularly were classified as never-
smokers.
Skin-prick tests and serum IgE
A standard set of 12 airborne allergens, birch (10
Histamine Equivalent Prick (HEP)), timothy grass
(10 HEP), mugwort (10 HEP), cat (10 HEP), dog (10
HEP), cow (1:100), horse (10 HEP), Alternaria
alternata (5mg/ml), Cladosporium herbarum
(5mg/ml), Dermatophagoides pteronyssinus (10
HEP), Dermatophagoides farinae (10 HEP), and
cockroach (1:100) with a positive (histaminedihy-
drochloride 10mg/ml) and negative (solvent) con-
trol was used throughout the study (Solu-Prick SQ,
ALK A/S, Copenhagen, Denmark). A wheal diameter
4¼ (i.e. equal or greater than) 3mm indicated a
positive test result.12 The subject was considered
to have atopy if there was at least one positive
reaction in the skin-prick test. Total serum IgE was
measured using the Pharmacia CAP System (Uppsa-
la, Sweden) according to the manufacturer’s
instructions.
Measurement of BHR; the methacholine
challenge test
Methacholine was delivered using the Spira Electro
II dosimeter (Spira Oy, H.ameenlinna, Finland) at
the doses of 18, 72, 270, 810 and 2600 mg of
methacholine.13 In the absence of a 20% fall in FEV1
from the baseline after the first methacholine dose,
the second dose was given, and the procedure was
repeated till the response was obtained. If no
response was obtained even with the highest dose,
the subject was categorized as a nonreactor with-
out BHR. Lung function (baseline and challenged
FEV1 and FVC) was measured with the VitalographR
R2150 spirometer (Vitalograph Ltd., Buckingham,
UK). The methacholine challenge test has not been
found to affect the sputum analysis.14
Sputum analysis
Induced sputum samples were taken immediately
after the methacholine challenge test. Sputum was
induced by inhalation of 5ml of a 5% NaCl solution
from an ultrasonic nebulizer (Omron CX2, Omron,
Germany). Those individuals who showed hyper-
responsiveness in the methacholine test were
premedicated with 0.2mg salbutamol (Ventoline
Volumatic, Glaxo Wellcome, UK). Sputum eosino-
philia was assessed using a semi-quantitative
method.15 The more viscous parts of the samples
were applied to two microscope slides and were
air-dried and stained with eosin–methylene blue.
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Table 1 Subject characteristics among the Finns and the Russians
FIN RUS P value
N 581 307
Mean age, years (range) 40.5 (25–54) 39.2 (25–54) 0.026
Males, n (%) 255 (43.9) 112 (36.5) 0.039
Smoking habits, n (%)
Current 156 (26.9) 130 (42.3) o0.001
Former 79 (13.6) 28 (9.1) NS
Atopy, n (%) 221 (38.0) 71 (23.1) o0.001
Lung function, mean (range)
FEV1 % predicted 96.3 (71–125) 95.2 (71–128) NS
FEV1/FVC (%) 81.3 (66–98) 80.7 (59–99) NS
Wheezing ever, n (%) 109 (18.7) 57 (18.6) NS
Shortness of breath, n (%)n 90 (15.5) 97 (31.6) NS
Shortness of breath while wheezing, n (%)n 43 (7.4) 4 (1.3) NS
Waking with cough at night, n (%)n 164 (28.2) 78 (25.4) NS
Phlegm in the morning in winter, n (%) 94 (16.2) 78 (25.4) NS
Parental asthma 130 (22.4) 23 (7.5) o0.001
nDuring the last 12 months.
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Proportions of eosinophils were counted under a
light microscope, and a 3-grade scale of severity
was used; no eosinophilia (o5% eosinophils of all
nonsquamous cells), mild (5–10% eosinophils),
moderate to severe (410% eosinophils) For the
measurements of the total concentrations of ECP
and MPO, sputum samples were processed and
analysed further according to the method by Metso
et al. described in detail elsewhere.6 In brief, the
sputum samples were treated with dithiotreitol and
a cetyl-N,N,N-trimethylammonium bromide deter-
gent to lyse the cells and gather the total
quantities of ECP and MPO that have been released
into the supernatant. The supernatants were frozen
in 201C for further serial analyses. Total concen-
trations of ECP and MPO were finally determined
using commercially available immunoassay kits
(Pharmacia & Upjohn, Diagnostics, Uppsala, Swe-
den) according to the manufacturer’s instructions.
Statistical analyses
Continuous variables were presented as means (SD)
or medians (range). The significance of differences
between the groups was calculated by using the
chi-squared test for categorical data and by the t-
test for continuous data. When the data were not
normally distributed (ECP, MPO), the nonpara-
metric Mann–Whitney U test was used. A two-
tailed P-value o0.05 was considered significant.
Odds ratios (OR) and 95% confidence intervals (CI)
for sputum eosinophilia and BHR, adjusted for age,
sex and smoking, were calculated with a regression
analysis.
Results
The prevalence of sputum eosinophilia was 22.1%
(14.6% mild, 7.5% moderate to severe) among the
Finns and 19.0% (14.1% mild, 4.9% moderate to
severe) among the Russians. For BHR, the respec-
tive figure was 13.8% among the former and 13.4%
among the latter (Table 2).
Atopy and parental asthma occurred significantly
more frequently among the Finns than the Russians
(38.0% vs. 23.1%, Po0:001 for atopy, 22.4% vs.
7.5%, Po0:001 for parental asthma) (Table 1). No
significant differences between the countries were
observed in the occurrence of respiratory symp-
toms, wheezing ever, shortness of breath, shortness
of breath while wheezing, or cough at night during
the last 12 months, or sputum production in
mornings in winter (Table 1).
The sputum analysis showed that a significantly
higher median of sputum ECP concentration was
measured among the Russians than the Finns (548
vs. 343 mg/l, Po0:001). The median of sputum MPO
concentration was similarly higher among the
Russians, although the difference did not achieve
significance (2050 vs. 1533 mg/l, P ¼ 0:0815). As in
the case of sputum ECP, very high concentrations
were occasionally measured also for sputum MPO
among the Russians (Table 2).
Current smoking was a significant risk factor for
sputum eosinophilia in Russia (OR 3.05, 95% CI 1.22–
7.61), and a risk factor of borderline significance in
Finland (1.98, 0.94–4.16). BHR was identified as
another risk factor for sputum eosinophilia in Russia
(3.70, 1.40–9.74). None of the other factors tested,
age, gender, atopy, parental asthma, or wheezing,
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Table 2 Occurrence of sputum eosinophilia and bronchial hyper-responsiveness (BHR), the mean of PD20
methacholine, the medians of sputum eosinophil cationic protein (ECP) and myeloperoxidase (MPO)
concentrations, and the mean of total serum IgE among the Finns and the Russians
FIN RUS P-value
N 240 205
Sputum eosinophilia, n (%)
Mild 35 (14.6) 29 (14.1) NS
Moderate to severe 18 (7.5) 10 (4.9) NS
Sputum ECP, mg/l, median 343 548 o0.001
Range 99–7000 99–24,400
Sputum MPO, mg/l, median 1533 2050 0.0815
Range 399–48150 399–257,000
N 581 307
BHR, n (%)n 80 (13.8) 41 (13.4) NS
PD20 methacholine, mg, mean (SD) 2397.9 (566.0) 2425.5 (515.5) NS
Serum IgE, kU/l, mean (SD) 102.2 (255.6) 197.2 (376.6) o0.001
nResponsiveness (20% fall in FEV1) to methacholine at any of the 5 doses tested.
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showed to be significantly associated with the
occurrence of sputum eosinophilia in Finland or in
Russia (Table 3).
For BHR, male gender and current smoking
showed to be common risk factors both in Finland
(2.34, 1.38–3.97 for male gender, 2.14, 1.25–3.66
for current smoking) and in Russia (2.35, 1.04–5.34
for male gender, 2.79, 1.29–6.05 for current
smoking). In addition, an association of borderline
significance was found between BHR and atopy in
Finland (1.61, 0.98–2.63) (Table 4).
Discussion
We found that a considerable proportion of
individuals without clinically relevant lung function
impairment had sputum eosinophilia and BHR,
suggesting that bronchial inflammation in function-
ally normal individuals is common.
Previous studies have reported lower occurrences
of sputum eosinophilia in healthy adults.16,17 This
discrepancy between the present study and the
previous ones may largely be explained by the
exclusion of smokers and symptomatic subjects
from the latter, and by differences in methodology.
Much of the bronchial inflammation found here was
evidently associated with smoking. The Russians
smoked significantly more commonly than the
Finns, but, unexpectedly, no differences in the
occurrence or severity of sputum eosinophilia or
BHR could be found. Differences were, by contrast,
found in markers of eosinophil and neutrophil
activation. The median of sputum ECP concentra-
tions showed to be significantly higher among the
Russians, indicating that they had a higher number
of active sputum eosinophils and/or neutrophils.
The higher proportion of current smokers, of which
many may have suffered from early, unrecognized
COPD, apparently contribute to these higher ECP
levels among the Russians.5,18 The higher, albeit not
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Table 3 Risk factors for sputum eosinophilia (odds ratio (OR) and 95% confidence intervals (CI)) adjusted for age,
sex and smoking among the Finns and the Russians derived from a regression analysis
FIN RUS
OR (95% CI) P-value OR (95% CI) P-value
Age, years
o40 1 1
40–50 1.00 (0.33–3.02) 0.99 1.24 (0.36–4.23) 0.73
450 0.68 (0.34–1.35) 0.27 0.92 (0.43–1.97) 0.82
Gender
Female 1 1
Male 0.70 (0.35–1.41) 0.32 1.36 (0.56–3.27) 0.49
Current smoking
No 1 1
Yes 1.98 (0.94–4.16) 0.07 3.05 (1.22–7.61) 0.017
Atopy
No 1 1
Yes 0.68 (0.32–1.42) 0.30 1.14 (0.50–2.61) 0.76
Wheezing
No 1 1
Yes 1.96 (0.86–4.49) 0.11 0.53 (0.20–1.40) 0.19
Parental asthma
No 1 1
Yes 1.84 (0.88–3.83) 0.10 1.12 (0.28–4.44) 0.87
BHR
No 1 1
Yes 0.75 (0.30–1.84) 0.53 3.70 (1.40–9.74) 0.008
Determinants of sputum eosinophilia and BHR 951
significantly, median of sputum MPO concentrations
among the Russians further support this view.
ECP has been suggested to serve as a marker of
general granulocyte activation.18 Indeed, the most
recent research has provided evidence that ECP,
demonstrated by the use of anti-ECP monoclonal
antibodies, occurs in active neutrophils as well.19
As there is thus far no evidence of the production of
ECP by neutrophils (the presence of ECPmRNA), it
has been proposed that ECP is actively taken up
from the environment by neutrophils in situations
where both cell types are abundantly present.20
The fact that an acceptable sputum sample could
be obtained from a considerably higher proportion
of the Russians than the Finns, 41% vs. 67%, may
also largely be explained by the higher proportion
of current smokers among the Russians. Overall,
these success rates for an acceptable sputum
sample can be considered satisfactory in the
context of an epidemiological study with appar-
ently healthy individuals.
In the context of different cultures and lan-
guages, the use of objective, well-standardized
measurements in multinational studies is necessary.
The measurement of BHR has proved to have
several advantages in population studies; it is
reliable, not influenced by variations in symptom
perception or diagnostic trends and is related to
the underlying mechanisms of inflammatory bron-
chial diseases, such as asthma.21 However, BHR is
also associated with other diseases, respiratory and
cardiovascular, and can even occur without micro-
scopic evidence of inflammation suggesting that
other causes, besides inflammation, must also
exist.22 The available data mainly from Europe
show, not only the wide variation in the occurrence
of BHR between the countries, but also that high
levels of BHR are not confined to English-speaking
world.23
Current smoking proved to be a significant risk
factor for BHR among both the Finns and the
Russians. Several epidemiological studies have
provided evidence that regular cigarette smoking
may lead to BHR that is independent of lung
function impairment.24–26 The fact that smoking
was significantly associated with BHR in individuals
with virtually normal lung function, points further
to the possibility that smoking independently
causes BHR, and that BHR is not a consequence of
lung function impairment. Due to the overwhelm-
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Table 4 Risk factors for BHR (OR and 95% CI) adjusted for age, sex and smoking among the Finns and the Russians
derived from a regression analysis
FIN RUS
OR (95% CI) P-value OR (95% CI) P-value
Age, years
o40 1 1
40–50 0.70 (0.33–1.50) 0.36 2.20 (0.90–5.37) 0.084
450 1.19 (0.72–1.98) 0.49 0.88 (0.44–1.74) 0.70
Gender
Female 1 1
Male 2.34 (1.38–3.97) 0.0017 2.35 (1.04–5.34) 0.041
Current smoking
No 1 1
Yes 2.14 (1.25–3.66) 0.0055 2.79 (1.29–6.05) 0.009
Atopy
No 1 1
Yes 1.61 (0.98–2.64) 0.059 0.71 (0.29–1.73) 0.45
Wheezing
No 1 1
Yes 1.39 (0.78–2.48) 0.27 1.53 (0.69–3.37) 0.29
Parental asthma
No 1 1
Yes 1.40 (0.80–2.46) 0.24 0.63 (0.14–2.87) 0.55
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ing impact of smoking, the possibility that other
risk factors remain undetected, exists. However, a
regression analysis performed in a subpopulation
without current smokers did not provide any
additional information (data not shown). Among
the Finns, BHR was also associated with atopy,
whereas among the Russians, factors such as
persistent lung infections, coal burning of domestic
heating, or exposure to increased levels of sulphur
dioxide and particulate matter27 may, besides
smoking, be involved. This finding of atopy-asso-
ciated BHR among the Finns, together with the
significantly higher prevalence of atopy, provides
further support to the hypothesis that less urban,
old-fashioned living conditions may protect from
atopic diseases.27
Similar to BHR, current smoking appeared to be a
risk factor also for sputum eosinophilia in Russia
and, albeit weaker, in Finland. The association
between smoking and sputum eosinophilia has been
shown earlier in a small cohort of healthy adults.28
The mechanisms underlying this association be-
tween smoking and sputum eosinophilia may only
partly be understood. At the single cell level, the
production of IL-4 by peripheral blood mononuclear
cells has been found to be increased in smokers
compared with nonsmokers.29 Since IL-4 is the
critical cytokine in Th2 cell differentiation, a shift
of the Th1/Th2 balance towards a Th2 immunity in
smokers may occur. IL-4 promote the induction of
Th2 cells which control the proliferation and
activities of eosinophils and mast cells, enhancing
indirectly the growth of these cells.30 Moreover,
Hagiwara et al. showed recently that smoking
depletes cells spontaneously secreting Th1 cyto-
kines in the human airway. The number of IL-2 and
IFN-g-secreting BAL-cells were found to be extre-
mely decreased in smokers. After mitogen stimula-
tion, Th1-cytokine secreting cells were likewise
significantly decreased in smokers,31 favouring thus
the development of Th2 predominance in the
smoker’s lung. Smoking may also partly explain
the significantly higher total IgE levels among the
Russians. Elevation of the total IgE level has been
shown to be associated with smoking regardless of
skin reactivity to common allergens.32 Another
factor that may be involved, is parasitic infections,
that have been found to partly explain differences
in total IgE levels between Western and Eastern
societies.33
Despite the common risk factor, smoking, BHR
and sputum eosinophilia may also develop largely
independently from each other. Indeed, Rosi
et al.,34 by using a statistical approach and factor
analysis, showed that no correlation between
sputum parameters (eosinophil counts and ECP
concentrations) and baseline BHR or lung function
or the occurrence of respiratory symptoms could be
found in patients with chronic stable asthma. It was
concluded that none of these variables can be
predicted by measuring sputum cellular or bio-
chemical parameters, which, on the other hand,
confers sputum analysis an important independent
role in assessment and monitoring airway inflam-
mation in asthma.3 Although the ultimate role of
eosinophils in the pathogenesis of asthma remains
controversial,35 their value as a useful tool to
examine bronchial inflammation cannot be ques-
tioned.
In conclusion, sputum eosinophilia and BHR were
common among the Finns and Russians with normal
lung function. Current smoking was consistently
and significantly associated with BHR in both
countries and with sputum eosinophilia in Russia.
Atopy showed to be a risk factor, albeit weak, for
BHR in Finland only, suggesting that the aetiology of
BHR in these two countries may partly be different.
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